Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
This book describes the newest developments in antibody drug conjugates and immunotoxins, paving their way to clinical application. Lessons learned from the current state of the art are used to further improve our understanding of their mechanisms of acti
- PDF / 5,963,611 Bytes
- 191 Pages / 439.42 x 683.15 pts Page_size
- 113 Downloads / 336 Views
Ulf Grawunder Stefan Barth Editors
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
Milestones in Drug Therapy
Series editors Michael J. Parnham, Fraunhofer IME & Goethe University Frankfurt, Germany Jacques Bruinvels, Bilthoven, The Netherlands Advisory Board J.C. Buckingham, Imperial College School of Medicine, London, UK R.J. Flower, The William Harvey Research Institute, London, UK A.G. Herman, Universiteit Antwerpen, Antwerp, Belgium P. Skolnick, National Institute on Drug Abuse, Bethesda, MD, USA
More information about this series at http://www.springer.com/series/4991
Ulf Grawunder • Stefan Barth Editors
Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins
Editors Ulf Grawunder NBE-Therapeutics Ltd. Basel, Switzerland
Stefan Barth Faculty of Health Sciences University of Cape Town Cape Town, South Africa
ISSN 2296-6056 ISSN 2296-6064 (electronic) Milestones in Drug Therapy ISBN 978-3-319-46875-4 ISBN 978-3-319-46877-8 (eBook) DOI 10.1007/978-3-319-46877-8 Library of Congress Control Number: 2017937530 © Springer International Publishing AG 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer International Publishing AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland
Preface
The specific targeting of toxic substances to disease targets is a historic concept that was already developed by Paul Ehrlich more than 100 years ago, for which he coined the term “magic bullet” (Zauberkugel). A “magic bullet” should only destroy the target expressing disease entity, but leave target-negative cells unaffected. While Paul Ehrlich developed the “magic bullet” concept primarily in the area of infectious disease, this principle can also perfectly be applied to the field of oncology. Du
Data Loading...
